BIOMARKERS FOR EARLY DETERMINATION OF A CRITICAL OR LIFE THREATENING RESPONSE TO ILLNESS AND/OR TREATMENT RESPONSE

摘要

The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

主权项

1. A method of determining the likelihood of a test individual having a critical and/or life threatening response to a suspected illness, said method comprising:
(i) detecting and quantifying a level of each of two or more protein biomarkers in a sample from the test individual, wherein the test individual has not been diagnosed or differentially diagnosed as having the suspected illness, wherein said protein biomarkers are: complement fragment C5a (C5a), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), 10 kDa interferon gamma-induced protein (IP-10), soluble tyrosine kinase with immunoglobulin-like loop and epidermal growth factor domain-2 (sTie-2), soluble intercellular adhesion molecule-1 (sICAM-1), vascular endothelial growth factor A (VEGF), soluble vascular endothelial growth factor receptor 1 (sFlt-1), Chitinase-3-like protein 1 (CHI3L1), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), C-reactive protein (CRP), procalcitonin (PCT), Angiopoietin-like protein 3 (Ang-like 3), complement factor D (Factor D), or interleukin 18 binding protein (IL18bpa), endoglin (End), p-selectin (p-SEL), von Endothelial soluble Tie-2 Receptor (Tie-2) and Willibrand Factor (vWF) as set out in Table 1; (ii) comparing said quantified levels of said protein biomarkers to control levels of said protein biomarkers from a control population; and (iii) determining the differential levels for each biomarker in the comparison of step (ii) so as to make a determination as to whether said test individual is at an increased risk of having the critical and/or life threatening response.